Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

MAbs. 2022 Jan-Dec;14(1):2072455. doi: 10.1080/19420862.2022.2072455.


Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibody; neutralizing antibody; super-neutralizing antibody.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2*


  • Antibodies, Neutralizing
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants

Grant support

This work was supported by Discretionary Fund of the President of the University of Toyama (H.N.), Grant for the Promotion of National University Reform from the Ministry of Education, Culture, Sports, Science and Technology (H.N.), Grant from the Toyama Pharmaceutical Valley Development Consortium (H.N.), the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under grant number JP21am0101077 (T.O.), and JP21am0101093 (K.M.), Ministry of Education, Culture, Sports, Science and Technology grant 20H05773 (T.H.) and JST CREST Grant Number JPMJCR20H8 (T.H.), the Takeda Foundation (K.M.) and Joint Usage/Research Center program of Institute for Frontier Life and Medical Sciences, Kyoto University (K.M.).